Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Bibliographic Details
Title: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Authors: Shaw, Alice T, Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J, Cetnar, Jeremy, West, Howard, Camidge, D Ross, Socinski, Mark A, Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H, Borghaei, Hossein, Gold, Kathryn A, Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ou, Sai-Hong Ignatius
Source: In The Lancet Oncology February 2016 17(2):234-242
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(15)00488-X
Published in:The Lancet Oncology
Language:English